Immix Biopharma, Inc. 宣布，在其Nexicart-2临床试验中，所有四名微小残留病（MRD）阴性的患者均已转化为完全缓解（Complete Response）。这一积极数据标志着该候选疗法在特定患者群体中展现出了显著的疗效潜力。试验结果的公布，进一步推动了公司针对血液肿瘤的CAR-T细胞疗法研发进程。
Immix Biopharma, Inc. 宣布，在其Nexicart-2临床试验中，所有四名微小残留病（MRD）阴性的患者均已转化为完全缓解（Complete Response）。这一积极数据标志着该候选疗法在特定患者群体中展现出了显著的疗效潜力。试验结果的公布，进一步推动了公司针对血液肿瘤的CAR-T细胞疗法研发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.